An animal model of chronic cyclosporine nephrotoxicity

Renal Failure

Volumn 21, Issue 3-4, 1999, Pages 365-368

  Porter, George A ^a   Andoh, Takeshi F ^a   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ANIMAL TISSUE; ARTERY CONSTRICTION; AUTOIMMUNE DISEASE; CONFERENCE PAPER; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FIBROSIS; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ARTERY; URINARY EXCRETION;

EID: 0033047892     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.3109/08860229909085100     Document Type: Conference Paper

References (17)

1. Andoh TF, Burdmann EA, Bennett WM: Nephrotoxicity of immunosuppressive drugs-experimental and clinical observations. Semin Nephrol 17:34-45, 1997.
2. Rosen S, Greenfeld Z, Brezis M: Chronic cyclosporine-induced nephropathy in the rat. Transplantation 49:445-452, 1990.
3. Goldstein DJ, Zuech N, Sehgal V, Weinberg AD, Drusin R, Cohen D: Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression. Transplantation 63:664-668, 1997.
4. Lowe NJ, Wieder JM, Rosenbach A, Johnson K, Kunkel R, Bainbridge C, et al.: Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 35:710-719, 1996.
5. Vitale AT, Rodriguez A, Foster CS: Low-dose cydosporine A therapy in treating chronic, noninfectious uveitis. Ophthalmology 103:365-373, 1996.
6. Mihatsch MJ, Ryffel B, Gudat F: The differential diagnosis between rejection and cyclosporine toxichy. Kidney Int 48(Supp 52):S63-S69, 1995.
7. Andoh TF, Bennett WM: Chronic cyclosporine nephrotoxicity. Curr Opin Nephrol Hypertens 7:265-270, 1998.
8. Lafayette RA, Mayer G, Meyer TW: The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol 3:1892-1899, 1993.
9. Elzinga L, Rosen S, Bennett WM: Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake. J Am Soc Nephrol 4:214-221, 1993.
10. Schainuck LI, Striker GE, Cutler RE, et al.: Structural-functional correlations in renal disease. Part II: The correlations. Human Pathol 1:631-674, 1970.
11. Shihab FS, Andoh TF, Tanner AM, Bennett WM: Sodium depletion enhances fibrosis and the expression of TGF-beta-1 and matrix proteins in experimental chronic cyclosporine nephropathy. Am J Kid Dis 30:71-81, 1997.
12. Andoh TF, Gardner MP, Bennett WM: Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity. Transplantation 64:1236-1240, 1997.
13. Khanna A, Kapur S, Sharma V, Li B, Suthanthiran M: In-vivo hyperexpression of transforming growth factor-beta-1 in mice:stimulation by cyclosporine. Transplantation 63:1037-1039, 1997.
14. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Angiotensin II blockade decreases TGF-beta-1 and matrix proteins in cyclosporine nephropathy. Kid Int 52:660-673, 1997.
15. Pichler RH, Hugo C, Shankland SJ, Reed MJ, Bassuk JA, Andoh TF, et al.: Sparc is expressed in renal interstitial fibrosis and in renal vascular injury. Kid Int 50:1978-1989, 1996.
16. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kid Int 52:1497-1510, 1997.
17. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM: Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kid Internat 50:1089-1100, 1996.